ArticleHealth science reports2026

Weight-Reduction and Safety Profile of Once-Weekly Non-Comparable Biotherapeutic Subcutaneous Semaglutide Among People With Obesity: A Real-World Retrospective Study.

Md Rakibul Hasan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.